briakinumab造句

• Briakinumab was compared to etanercept and placebo in several double-blind trials.
• The monoclonal antibody briakinumab is not effective for people with active crohn's disease.
• On January 15, 2011, Abbott announced the withdrawal of its application to the US FDA and European regulators for briakinumab.
• The Psoriasis Area Severity Index ( PASI ) was reduced significantly better than under the comparator treatments . 81 82 % of patients under briakinumab, 40 56 % under etanercept, and 7 % under placebo reached PASI reduction of at least 75 %.